Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin

Journal of Immunology

Volumn 182, Issue 3, 2009, Pages 1674-1680

  Yang, Yao Hsu ^a,b   Chien, Daniel ^a   Wu, Meifang ^a,c   FitzGerald, John ^a   Grossman, Jennifer M ^a   Hahn, Bevra H ^a   Hwang, Kwan Ki ^a   Chen, Pojen P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PHOSPHOLIPID ANTIBODY; THROMBIN; MONOCLONAL ANTIBODY;

ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY MECHANISM; THROMBOSIS; ADOLESCENT; ADULT; AGED; ANTIBODY COMBINING SITE; BLOOD; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROTEIN BINDING;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBINS; BINDING SITES, ANTIBODY; FACTOR IXA; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROTEIN BINDING;

EID: 63149169674     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.182.3.1674     Document Type: Article

References (44)

1. Miyakis, S., M. D. Lockshin, T. Atsumi, D. W. Branch, R. L. Brey, R. Cervera, R. H. Derksen, P. G. De Groot, T. Koike, P. L. Meroni, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4: 295-306.
2. Lockshin, M. D. 2006. Update on antiphospholipid syndrome. Bull. Hosp. J. Dis. 64: 57-59.
3. Bertolaccini, M. L., and M. A. Khamashta. 2006. Laboratory diagnosis and management challenges in the antiphospholipid syndrome. Lupus 15: 172-178.
4. Pierangeli, S. S., P. P. Chen, and E. B. Gonzalez. 2006. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr. Opin. Hematol. 13: 366-375.
5. 2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA 87: 4120-4124.
6. Fleck, R. A., S. I. Rapaport, and L. V. Rao. 1988. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 72: 512-519.
7. Oosting, J. D., R. H. W. M. Derksen, I. W. G. Bobbink, T. M. Hackeng, B. N. Bouma, and P. G. de Groot. 1993. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 81: 2618-2625.
8. Rand, J. H., X. X. Wu, H. A. M. Andree, C. J. Lockwood, S. Guller, J. Scher, and P. C. Harpel. 1997. Pregnancy loss in the antiphospholipid-antibody syndrome: a possible thrombogenic mechanism. N. Engl. J. Med. 337: 154-160.
9. Carson, C. W., P. C. Comp, A. R. Rezaie, N. L. Esmon, and C. T. Esmon. 2000. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J. Rheumatol. 27: 384-390.
10. Hwang, K., J. Grossman, S. Visvanathan, R. Chukwuocha, V. Woods, D. Le, B. Hahn, and P. Chen. 2001. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J. Immunol. 167: 7192-7198.
11. Forastiero, R. R., M. E. Martinuzzo, and G. J. Broze. 2003. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J. Thromb. Haemost. 1: 718-724.
12. Hwang, K. K., C. D. Yang, W. Yan, J. M. Grossman, B. H. Hahn, and P. P. Chen. 2003. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum. 48: 1622-1630.
13. Hurtado, V., R. Montes, J. C. Gris, M. L. Bertolaccini, A. Alonso, M. A. Martinez-Gonzalez, M. A. Khamashta, K. Fukudome, D. A. Lane, and J. Hermida. 2004. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood 104: 1369-1374.
14. Yang, C. D., K. K. Hwang, W. Yan, K. Gallagher, J. FitzGerald, J. M. Grossman, B. H. Hahn, and P. P. Chen. 2004. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J. Immunol. 172: 5765-5773.
15. Lu, C. S., A. A. Horizon, K. K. Hwang, J. Fitzgerald, W. S. Lin, B. H. Hahn, D. J. Wallace, A. L. Metzger, M. H. Weisman, and P. P. Chen. 2005. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum. 52: 4018-4027.
16. Cesarman-Maus, G., N. P. Rios-Luna, A. B. Deora, B. Huang, R. Villa, C. Cravioto Mdel, D. Alarcon-Segovia, J. Sanchez-Guerrero, and K. A. Hajjar. 2006. Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. Blood 107: 4375-4382.
17. Yang, Y. H., K. K. Hwang, J. FitzGerald, J. M. Grossman, M. Taylor, B. H. Hahn, and P. P. Chen. 2006. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J. Immunol. 177: 8219-8225.
18. Giannakopoulos, B., F. Passam, S. Rahgozar, and S. A. Krilis. 2007. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109: 422-430.
19. Meroni, P. L. 2008. Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. J. Autoimmun. 30: 99-103.
20. Kornberg, A., M. Blank, S. Kaufman, and Y. Shoenfeld. 1994. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J. Immunol. 153: 1328-1332.
21. Amengual, O., T. Atsumi, M. A. Khamashta, and G. R. V. Hughes. 1998. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb. Haemost. 79: 276-281.
22. Zhou, H., A. S. Wolberg, and R. A. Roubey. 2004. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 104: 2353-2358.
23. Borrell, M., N. Sala, C. de Castellanau, S. Lopez, M. Gari, and J. Foncuberta. 1992. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb. Haemost. 68: 268-272.
24. Holers, V., G. Girardi, L. Mo, J. Guthridge, H. Molina, S. Pierangeli, R. Espinola, L. Xiaowei, D. Mao, C. Vialpando, and J. Salmon. 2002. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195: 211-220.
25. Salmon, J. E., G. Girardi, and M. D. Lockshin. 2007. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Natl. Clin. Pract. Rheumatol. 3: 140-147.
26. Dahlback, B. 2000. Blood coagulation. Lancet 355: 1627-1632.
27. Esmon, C. T. 2000. Regulation of blood coagulation. Biochim. Biophys. Acta 1477: 349-360.
28. Bolton-Maggs, P. H., and K. J. Pasi. 2003. Haemophilias A and B. Lancet 361: 1801-1809.
29. Bertina, R. M. 2003. Elevated clotting factor levels and venous thrombosis. Pathophysiol. Haemost. Thromb. 33: 395-400.
30. Pearson, J. D. 1999. Endothelial cell function and thrombosis. Baillieres Best Pract. Res. Clin. Haematol. 12: 329-341.
31. Kottke-Marchant, K., and A. Duncan. 2002. Antithrombin deficiency: issues in laboratory diagnosis. Arch. Pathol. Lab. Med. 126: 1326-1336.
32. Pierangeli, S. S., X. W. Liu, R. Espinola, T. Olee, M. Zhu, N. E. Harris, and P. P. Chen. 2000. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb. Haemost. 84: 388-395.
33. Furie, B., D. H. Bing, R. J. Feldmann, D. J. Robison, J. P. Burnier, and B. C. Furie. 1982. Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases. J. Biol. Chem. 257: 3875-3882.
34. 2GP1 antibodies from two patients with the anti-phospholipid syndrome reveals three species of antibodies. Br. J. Haematol. 105: 102-109.
35. Zhao, Y., R. Rumold, A. E. Ahmed, D. T. Le, B. H. Hahn, V. L. Woods, Jr., and P. P. Chen. 1999. An IgG anti-prothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum. 42: 2132-2138.
36. 2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum. 56: 1638-1647.
37. Wilson, W. A., A. E. Gharavi, T. Koike, M. D. Lockshin, D. W. Branch, J. C. Piette, R. Brey, R. Derksen, E. N. Harris, G. R. V. Hughes, et al. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 42: 1309-1311.
38. Wiebe, E. M., A. R. Stafford, J. C. Fredenburgh, and J. I. Weitz. 2003. Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J. Biol. Chem. 278: 35767-35774.
39. Stenflo, J. 1991. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 78: 1637-1651.
40. Pike, R. N., A. M. Buckle, B. F. le Bonniec, and F. C. Church. 2005. Control of the coagulation system by serpins: getting by with a little help from glycosaminoglycans. FEBS J. 272: 4842-4851.
41. Martinez-Maza, O., and S. Britton. 1983. Frequencies of the separate human B cell subsets activatable to Ig secretion by Epstein-Barr virus and pokeweed mitogen. J. Exp. Med. 157: 1808-1814.
42. Greenber, C. S., and C. L. Orthner. 1999. Blood coagulation and fibrinolysis. In Wintrobe's Clinical Hematology, 10th Ed. G. R. Lee, J. Foerster, J. Lukens, F. Paraskevas, J. P. Greer, and G. M. Rogers, eds. Williams & Wilkins, Baltimore, MD, pp. 684-764.
43. Walker, I. D. 1997. Congenital thrombophilia. Baillieres Clin. Obstet. Gynaecol. 11: 431-445.
44. Bick, R. L., and H. Kaplan. 1998. Syndromes of thrombosis and hypercoagulability: congenital and acquired causes of thrombosis. Med. Clin. North Am. 82: 409-458.